NUT Carcinoma
Conditions
Keywords
NUTM1, Pulmonary NUT carcinoma, Retrospective cohort, Multicenter
Brief summary
This study is a multi-center, retrospective observational study of patients with lung NUT carcinoma. Existing clinical records from participating hospitals will be reviewed to describe patient characteristics, treatments, and outcomes. No study-related interventions will be performed. Data will be de-identified to protect patient privacy.
Detailed description
This is a multi-center, retrospective observational cohort study of lung NUT carcinoma. Eligible patients diagnosed with lung NUT carcinoma at participating hospitals will be identified based on pathology with supportive evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion. Data will be extracted from existing medical records and follow-up documentation, including demographics, tumor characteristics, staging, treatments, and outcomes. When available, routine-care pathology information and imaging data will be collected and de-identified. Primary outcome: progression-free survival (PFS). Secondary outcomes: overall survival (OS) and other routinely documented outcomes when available. No new drugs, devices, procedures, or additional tests will be provided as part of this research. All data will be de-identified and stored with access controls according to applicable regulations and ethics approvals at each participating site.
Interventions
OTHERStandard-of-care anticancer treatment (retrospective)
Treatments received as part of routine clinical care and recorded retrospectively in medical records, which may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy. No study-related intervention will be assigned or provided. This observational study only collects and analyzes de-identified real-world treatment and outcome data.
Sponsors
Three Gorges Hospital of Chongqing University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed pulmonary (lung) NUT carcinoma. * Evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion, per local pathology report. * Diagnosed and/or treated at a participating hospital during the study period. * Availability of sufficient medical record data to abstract key baseline characteristics, treatments, and outcomes.
Exclusion criteria
* Primary tumor site not in the lung. * Records insufficient to confirm the diagnosis of pulmonary NUT carcinoma. * No follow-up or outcome information available after diagnosis (insufficient for survival/outcome assessment).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From diagnosis through study completion (up to May 2026) | Time from initial diagnosis (index date) to first documented disease progression per routine clinical assessment or death from any cause, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From diagnosis through study completion (up to May 2026) | Time from initial diagnosis (index date) to death from any cause. |
Countries
China
Outcome results
None listed